Compare Global X Cybersecurity (BUG) vs Merck & Co., Inc. (MRK) Price & Performance

Global X CybersecurityTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Global X Cybersecurity vs Merck & Co., Inc. — how do they compare? Global X Cybersecurity trades at $42.5, while Merck & Co., Inc. trades at $124.16 (market cap $298.31B). The key difference: Merck & Co., Inc. pays a 2.82% dividend while Global X Cybersecurity pays none, and Global X Cybersecurity is trading nearer its 52-week high, Merck & Co., Inc. nearer its low. Which is the better fit depends on your goals.

	BUG	MRK
Sector	Sector/Thematic	Health
52-Week High	$41.99	$129.52
52-Week Low	$23.30	$77.60
Market Cap	—	$298.31B
Enterprise Value	—	$341.72B
Dividend Yield	—	2.82%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Cybersecurity

BUG trades at $39.64, up 0.69% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces resistance near $40 and support at $39. Recent news highlights strong cybersecurity sector tailwinds, with global spending exceeding $300 billion in 2026, though the ETF faces competition from semiconductor-focused alternatives.

Outlook remains positive given cybersecurity's essential role in AI-driven cloud expansion, but valuation premiums and sector competition pose risks. The stock's performance hinges on continued enterprise budget growth and its ability to maintain relevance against disruptive AI technologies.

Merck & Co., Inc.

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BUG

Cybersecurity ETF BUG gained 29% in 6 months, showing strong AI-security theme growth beyond CrowdStrike's 60%.24/7 Wall Street · 19 hours agoBullish View details →

MRK

Generative AI in drug discovery market to reach $0.86B by 2030, growing at 27% CAGR driven by faster drug development and AI advancesResearchandmarkets.Com · 4 days agoBullish View details →

About Global X Cybersecurity

BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.